EGFR and cancer: For example, immunoliposomes have been prepared using anti-EGFR antibodies as targeting moieties and were used to deliver drugs such as 5-fluorouracil,22 cisplatin23 and doxorubicin24 to cancer cells in vivo, with moderate to significant improvements in cytotoxicity and cell selectivity compared to non-targeted liposomes.